SlideShare a Scribd company logo
PURE (Prospective Urban Rural
Epidemiology)
PURE (Prospective Urban Rural Epidemiology)
S Yusuf (McMaster University, Hamilton, ON)
European Society of Cardiology 2011 Congress


• A survey of 153 996 adults to examine the relationship of societal influences on
  human lifestyle behaviors, CV risk factors, and incidence of chronic
  noncommunicable diseases
•   Time period: 2003–2009
• Population categories:
     Urban and rural communities in countries categorized as high-income
     (Canada, Sweden, and United Arab Emirates), upper-middle-income
     (Argentina, Brazil, Chile, Malaysia, Poland, South Africa, and Turkey), lower-
     middle-income (China, Colombia, and Iran), and low-income (Bangladesh,
     India, Pakistan, and Zimbabwe)
• Analyzed the use of antiplatelets, beta blockers, ACE inhibitors or ARBs,
  statins, and other agents among persons with CHD or stroke


ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; CHD=coronary heart
disease
PURE: Results (by economic status)

CV drug use for secondary prevention among patients with CHD or
stroke, by nation economic status
CV drug category       High-income (%)   Upper-middle          Lower-middle   Low-income   Overall
                                         income (%)            income (%)     (%)

Antiplatelets          62.0              24.6                  21.9           8.8          25.3

Beta blockers          40.0              25.4                  10.2           9.7          17.4

ACE inhibitors or ARBs 49.8              30.0                  11.1           5.2          19.5

BP-lowering agents     73.8              48.4                  37.4           19.2         41.8

Statins                66.5              17.6                  4.3            3.3          14.6

All decreasing trends from higher- to lower-income, p<0.0001
PURE: Results (urban vs rural)

CV drug use for secondary prevention among patients with CHD or
stroke, urban vs rural populations across all surveyed countries
CV drug category        Urban (%)         Rural (%)


Antiplatelets           27.7              21.5

Beta blockers           20.3              13.1

ACE inhibitors or ARBs 22.3               15.4

BP-lowering agents      47.1              33.7

Statins                 17.2              10.6

All differences urban vs rural, p<0.001
PURE: Commentary*

"These are the cheapest, the safest, and the most effective drugs. And yet we have
a collective global failure."
                                                                    - Dr Salim Yusuf


"A real improvement in global cardiovascular health could likely be obtained through
preventive strategies focused on the well-known risk factors, including lifestyle
changes."

                                                                                 - Dr Aldo Pietro Maggioni




*All comments from PURE: CV drugs underused in poor nations, rural populations
(http://www.theheart.org/article/1268617.do)
Become a member of http://www.theheart.org
    Become a fan on Facebook: http://www.facebook.com/theheartorg
          Follow us on Twitter: http://www.twitter.com/theheartorg

theheart.org is the leading online source of independent cardiology news.
We are the top provider of news and opinions for over 100 000 physicians.

More Related Content

Similar to PURE trial - Summary & Results

The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8 The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8
Utai Sukviwatsirikul
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...MedicineAndHealthUSA
 
Million-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptxMillion-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptx
derek462361
 
Ckd 2016 100 1
Ckd 2016 100 1Ckd 2016 100 1
Ckd 2016 100 1
FarragBahbah
 
A stitch in time - Vash Mungal-Singh
A stitch in time - Vash Mungal-SinghA stitch in time - Vash Mungal-Singh
A stitch in time - Vash Mungal-Singh
NCAS1
 
Beta bloqueadores en hta y falla cardíaca.
Beta bloqueadores en hta y falla cardíaca.Beta bloqueadores en hta y falla cardíaca.
Beta bloqueadores en hta y falla cardíaca.
Ascani Nicaragua
 
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxHF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
JEEWANKUMAR14
 
Jaume Marrugat de la Iglesia. Debates en Cardiología
Jaume Marrugat de la Iglesia. Debates en CardiologíaJaume Marrugat de la Iglesia. Debates en Cardiología
Jaume Marrugat de la Iglesia. Debates en Cardiología
Sociedad Española de Cardiología
 
Telehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSS
Telehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSSTelehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSS
Telehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSS
VSee
 
2015 Report: Medicines in Development for Heart Disease & Stroke
2015 Report: Medicines in Development for Heart Disease & Stroke2015 Report: Medicines in Development for Heart Disease & Stroke
2015 Report: Medicines in Development for Heart Disease & Stroke
PhRMA
 
Managing Type 2 Diabetes
Managing Type 2 DiabetesManaging Type 2 Diabetes
Managing Type 2 Diabetes
Lionel Wolberger
 
The cost of doing nothing
The cost of doing nothing The cost of doing nothing
The cost of doing nothing
Department of Health
 
Heart Failure biomarkers
Heart Failure biomarkersHeart Failure biomarkers
Heart Failure biomarkers
drucsamal
 
ueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammedueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammed
ueda2015
 
Approach to Hypertension - Combination therapy.pptx
Approach to Hypertension - Combination therapy.pptxApproach to Hypertension - Combination therapy.pptx
Approach to Hypertension - Combination therapy.pptx
drsbansal2000
 
ASCOT-LLA trial - Summary & Results
ASCOT-LLA trial - Summary & ResultsASCOT-LLA trial - Summary & Results
ASCOT-LLA trial - Summary & Results
theheart.org
 
An Introduction to CVD Racial Disparities
An Introduction to CVD Racial DisparitiesAn Introduction to CVD Racial Disparities
An Introduction to CVD Racial Disparities
Dr. Tony Shackelford DHA, CCP
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014
Muhamed Al Rohani
 
arterial health in hypertension
 arterial health in hypertension arterial health in hypertension
arterial health in hypertension
Kyaw Win
 

Similar to PURE trial - Summary & Results (20)

The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8 The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
 
Million-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptxMillion-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptx
 
ckd
ckdckd
ckd
 
Ckd 2016 100 1
Ckd 2016 100 1Ckd 2016 100 1
Ckd 2016 100 1
 
A stitch in time - Vash Mungal-Singh
A stitch in time - Vash Mungal-SinghA stitch in time - Vash Mungal-Singh
A stitch in time - Vash Mungal-Singh
 
Beta bloqueadores en hta y falla cardíaca.
Beta bloqueadores en hta y falla cardíaca.Beta bloqueadores en hta y falla cardíaca.
Beta bloqueadores en hta y falla cardíaca.
 
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxHF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
 
Jaume Marrugat de la Iglesia. Debates en Cardiología
Jaume Marrugat de la Iglesia. Debates en CardiologíaJaume Marrugat de la Iglesia. Debates en Cardiología
Jaume Marrugat de la Iglesia. Debates en Cardiología
 
Telehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSS
Telehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSSTelehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSS
Telehealth for lifestyle interventions - Laurence Girard, FruitStreet - TFSS
 
2015 Report: Medicines in Development for Heart Disease & Stroke
2015 Report: Medicines in Development for Heart Disease & Stroke2015 Report: Medicines in Development for Heart Disease & Stroke
2015 Report: Medicines in Development for Heart Disease & Stroke
 
Managing Type 2 Diabetes
Managing Type 2 DiabetesManaging Type 2 Diabetes
Managing Type 2 Diabetes
 
The cost of doing nothing
The cost of doing nothing The cost of doing nothing
The cost of doing nothing
 
Heart Failure biomarkers
Heart Failure biomarkersHeart Failure biomarkers
Heart Failure biomarkers
 
ueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammedueda2012 do we still need high doses-d.mohammed
ueda2012 do we still need high doses-d.mohammed
 
Approach to Hypertension - Combination therapy.pptx
Approach to Hypertension - Combination therapy.pptxApproach to Hypertension - Combination therapy.pptx
Approach to Hypertension - Combination therapy.pptx
 
ASCOT-LLA trial - Summary & Results
ASCOT-LLA trial - Summary & ResultsASCOT-LLA trial - Summary & Results
ASCOT-LLA trial - Summary & Results
 
An Introduction to CVD Racial Disparities
An Introduction to CVD Racial DisparitiesAn Introduction to CVD Racial Disparities
An Introduction to CVD Racial Disparities
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014
 
arterial health in hypertension
 arterial health in hypertension arterial health in hypertension
arterial health in hypertension
 

More from theheart.org

ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentation
theheart.org
 
AHA 2012 Research Highlights
AHA 2012 Research HighlightsAHA 2012 Research Highlights
AHA 2012 Research Highlights
theheart.org
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation
theheart.org
 
TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation
theheart.org
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentation
theheart.org
 
CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results
theheart.org
 
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global EndpointONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
theheart.org
 
OASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACCOASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACC
theheart.org
 
IDEAL trial - Summary & Results
IDEAL trial - Summary & ResultsIDEAL trial - Summary & Results
IDEAL trial - Summary & Results
theheart.org
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
theheart.org
 
RIVAL trial - Summary & Results
RIVAL trial - Summary & ResultsRIVAL trial - Summary & Results
RIVAL trial - Summary & Results
theheart.org
 
ACT trial - Summary & Results
ACT trial - Summary & ResultsACT trial - Summary & Results
ACT trial - Summary & Results
theheart.org
 
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & ResultsP-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
theheart.org
 
TRITON-TIMI 38 trial - Summary & Results
TRITON-TIMI 38 trial - Summary & ResultsTRITON-TIMI 38 trial - Summary & Results
TRITON-TIMI 38 trial - Summary & Results
theheart.org
 
SHIFT trial - Summary & Results
SHIFT trial - Summary & ResultsSHIFT trial - Summary & Results
SHIFT trial - Summary & Results
theheart.org
 
PROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & ResultsPROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & Results
theheart.org
 
PRELUDE trial - Summary & Results
PRELUDE trial - Summary & ResultsPRELUDE trial - Summary & Results
PRELUDE trial - Summary & Results
theheart.org
 
ALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & ResultsALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & Results
theheart.org
 
PRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & ResultsPRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & Results
theheart.org
 
OSCAR trial - Summary & Results
OSCAR trial - Summary & ResultsOSCAR trial - Summary & Results
OSCAR trial - Summary & Results
theheart.org
 

More from theheart.org (20)

ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentation
 
AHA 2012 Research Highlights
AHA 2012 Research HighlightsAHA 2012 Research Highlights
AHA 2012 Research Highlights
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation
 
TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentation
 
CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results
 
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global EndpointONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
 
OASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACCOASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACC
 
IDEAL trial - Summary & Results
IDEAL trial - Summary & ResultsIDEAL trial - Summary & Results
IDEAL trial - Summary & Results
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
 
RIVAL trial - Summary & Results
RIVAL trial - Summary & ResultsRIVAL trial - Summary & Results
RIVAL trial - Summary & Results
 
ACT trial - Summary & Results
ACT trial - Summary & ResultsACT trial - Summary & Results
ACT trial - Summary & Results
 
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & ResultsP-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
 
TRITON-TIMI 38 trial - Summary & Results
TRITON-TIMI 38 trial - Summary & ResultsTRITON-TIMI 38 trial - Summary & Results
TRITON-TIMI 38 trial - Summary & Results
 
SHIFT trial - Summary & Results
SHIFT trial - Summary & ResultsSHIFT trial - Summary & Results
SHIFT trial - Summary & Results
 
PROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & ResultsPROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & Results
 
PRELUDE trial - Summary & Results
PRELUDE trial - Summary & ResultsPRELUDE trial - Summary & Results
PRELUDE trial - Summary & Results
 
ALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & ResultsALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & Results
 
PRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & ResultsPRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & Results
 
OSCAR trial - Summary & Results
OSCAR trial - Summary & ResultsOSCAR trial - Summary & Results
OSCAR trial - Summary & Results
 

Recently uploaded

Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 

Recently uploaded (20)

Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 

PURE trial - Summary & Results

  • 1. PURE (Prospective Urban Rural Epidemiology)
  • 2. PURE (Prospective Urban Rural Epidemiology) S Yusuf (McMaster University, Hamilton, ON) European Society of Cardiology 2011 Congress • A survey of 153 996 adults to examine the relationship of societal influences on human lifestyle behaviors, CV risk factors, and incidence of chronic noncommunicable diseases • Time period: 2003–2009 • Population categories: Urban and rural communities in countries categorized as high-income (Canada, Sweden, and United Arab Emirates), upper-middle-income (Argentina, Brazil, Chile, Malaysia, Poland, South Africa, and Turkey), lower- middle-income (China, Colombia, and Iran), and low-income (Bangladesh, India, Pakistan, and Zimbabwe) • Analyzed the use of antiplatelets, beta blockers, ACE inhibitors or ARBs, statins, and other agents among persons with CHD or stroke ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; CHD=coronary heart disease
  • 3. PURE: Results (by economic status) CV drug use for secondary prevention among patients with CHD or stroke, by nation economic status CV drug category High-income (%) Upper-middle Lower-middle Low-income Overall income (%) income (%) (%) Antiplatelets 62.0 24.6 21.9 8.8 25.3 Beta blockers 40.0 25.4 10.2 9.7 17.4 ACE inhibitors or ARBs 49.8 30.0 11.1 5.2 19.5 BP-lowering agents 73.8 48.4 37.4 19.2 41.8 Statins 66.5 17.6 4.3 3.3 14.6 All decreasing trends from higher- to lower-income, p<0.0001
  • 4. PURE: Results (urban vs rural) CV drug use for secondary prevention among patients with CHD or stroke, urban vs rural populations across all surveyed countries CV drug category Urban (%) Rural (%) Antiplatelets 27.7 21.5 Beta blockers 20.3 13.1 ACE inhibitors or ARBs 22.3 15.4 BP-lowering agents 47.1 33.7 Statins 17.2 10.6 All differences urban vs rural, p<0.001
  • 5. PURE: Commentary* "These are the cheapest, the safest, and the most effective drugs. And yet we have a collective global failure." - Dr Salim Yusuf "A real improvement in global cardiovascular health could likely be obtained through preventive strategies focused on the well-known risk factors, including lifestyle changes." - Dr Aldo Pietro Maggioni *All comments from PURE: CV drugs underused in poor nations, rural populations (http://www.theheart.org/article/1268617.do)
  • 6. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorg theheart.org is the leading online source of independent cardiology news. We are the top provider of news and opinions for over 100 000 physicians.